LEXINGTON, Mass. — The world’s second-most valuable pharma company is on the hunt for its next big breakthrough, and it thinks the sequel to Ozempic or Wegovy could be discovered in Boston.
On Wednesday, the Danish diabetes and obesity drugmaker Novo Nordisk unveiled its new R&D facility just outside the city, pitching it as a US flagship to match its headquarters in Denmark, and an important step towards life after its blockbuster GLP-1 drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.